news

 

February 2019 AROMICS launches BERMES project, with the financing support of Horizon 2020 SME instrument phase 2 program

 
AROMICS launches BERMES project, with the financing support of Horizon 2020 SME instrument phase 2 program

The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposure